Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 214

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

Open access
Capodanno, Davide, Mehran, Roxana, Valgimigli, Marco, Baber, Usman, Windecker, Stephan, Vranckx, Pascal, Dangas, George, Rollini, Fabiana, Kimura, Takeshi, Collet, Jean-Philippe, Gibson, C. Michael, Steg, Philippe Gabriel, Lopes, Renato D., Gwon, Hyeon-Cheol, Storey, Robert F., Franchi, Francesco, Bhatt, Deepak L., Serruys, Patrick W., Angiolillo, Dominick J.·2018·Nature Reviews Cardiology
DOI 10.1038/s41569-018-0049-1
Open this paper in CoChat — free account

Abstract

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly known as aspirin) has been the mainstay of treatment for decades owing to its capacity to reduce the risk of ischaemic events. Accordingly, novel antithrombotic therapies have been traditionally tested on a background of acetylsalicylic acid therapy. Although the adjunctive use of such antithrombotic therapies can potentially further reduce the risk of ischaemic events, these agents are also inevitably associated with an increased risk of bleeding. However, acetylsalicylic acid also increases the risk of bleeding, challenging the paradigm that this agent should remain the cornerstone of antiplatelet treatment when alternative antithrombotic agents are also used. Many antithrombotic compounds are characterized by increased potency and consistent efficacy, which might lessen the need for concomitant acetylsalicylic acid. Accordingly, numerous investigations are testing the hypothesis that acetylsalicylic acid-sparing regimens based on newer antithrombotic agents might have an increased net benefit for individual patients owing to the reduction in bleeding risk, without a trade-off in efficacy. This Review summarizes the state of the art relating to antithrombotic approaches with and without acetylsalicylic acid for the prevention of cardiovascular disease and cardioembolic stroke. Discussion of the scientific rationale, from bench to bedside, for ongoing studies of acetylsalicylic acid-free pharmacological strategies is included.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-018-0049-1

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 214

Metadata

Authors
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J.-P., Gibson, C. M., Steg, P. G., Lopes, R. D., Gwon, H.-C., Storey, R. F., Franchi, F., Bhatt, D. L., Serruys, P. W., & Angiolillo, D. J.
Venue
Nature Reviews Cardiology
Publisher
Springer Science and Business Media LLC
Published
2018-07-04
Volume
15
Issue
8
Pages
480-496
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
DOI
10.1038/s41569-018-0049-1
OpenAlex
W2809722890
Cited by
214
References
24
FWCI
8.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. https://app.cochat.ai/papers/10.1038/s41569-018-0049-1
The paper
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J.-P., Gibson, C. M., Steg, P. G., Lopes, R. D., Gwon, H.-C., Storey, R. F., Franchi, F., Bhatt, D. L., Serruys, P. W., & Angiolillo, D. J. (2018). Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-018-0049-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.